Remestemcel-L Reduces Inflammatory Biomarkers Predictive of High Mortality in Acute Graft Versus Host Disease
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced results presented at the 62nd annual meeting American Society of Hematology (ASH …